HELUS PHARMA INC
HELPNASDAQ🏆 #2672 by market capEarnings Nov 11US Equity
$10.71▼ $0.21 (−1.92%)
Pre-market · at closeTrack HELP
Get earnings, price moves & breaking news on Telegram
24h▼ 1.9%
7d▲ 5.0%
14d▲ 1.4%
30d▼ 12.7%
ytd▲ 30.1%
1y▲ 48.9%
🏦Market Cap
$664M
Small Cap
📈Revenue Growth (YoY)
-9561.6%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $10.52 – $11.16
- 52-Week Range
- $3.76 – $15.15
- Volume (shares)
- 33,225
- Avg Volume (shares)
- —
- Shares Outstanding
- 62.0M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -2.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.35
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +116.1%
HELUS PHARMA INC
HELPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
−$45M▼ −9561.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.3%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$142M▼ −1.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$134M▲ +29.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
52.3M▲ +116.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$166M▼ −$29M YoY
StockOtter · stockotter.spaceAbout HELUS PHARMA INC
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.